200 related articles for article (PubMed ID: 28888210)
21. Synergistic therapeutic effects of a tumor targeting antibody fragment, fused to interleukin 12 and to tumor necrosis factor alpha.
Halin C; Gafner V; Villani ME; Borsi L; Berndt A; Kosmehl H; Zardi L; Neri D
Cancer Res; 2003 Jun; 63(12):3202-10. PubMed ID: 12810649
[TBL] [Abstract][Full Text] [Related]
22. Melittin-MIL-2 fusion protein as a candidate for cancer immunotherapy.
Liu M; Wang H; Liu L; Wang B; Sun G
J Transl Med; 2016 Jun; 14(1):155. PubMed ID: 27246873
[TBL] [Abstract][Full Text] [Related]
23. Chimeric TNT-3 antibody/murine interferon-gamma fusion protein for the immunotherapy of solid malignancies.
Mizokami MM; Hu P; Khawli LA; Li J; Epstein AL
Hybrid Hybridomics; 2003 Aug; 22(4):197-207. PubMed ID: 14511565
[TBL] [Abstract][Full Text] [Related]
24. Immunocytokines for cancer treatment: past, present and future.
Neri D; Sondel PM
Curr Opin Immunol; 2016 Jun; 40():96-102. PubMed ID: 27060634
[TBL] [Abstract][Full Text] [Related]
25. Antibody-cytokine fusion proteins: harnessing the combined power of cytokines and antibodies for cancer therapy.
Helguera G; Morrison SL; Penichet ML
Clin Immunol; 2002 Dec; 105(3):233-46. PubMed ID: 12498805
[No Abstract] [Full Text] [Related]
26. Designing cell-targeted therapeutic proteins reveals the interplay between domain connectivity and cell binding.
Robinson-Mosher A; Chen JH; Way J; Silver PA
Biophys J; 2014 Nov; 107(10):2456-66. PubMed ID: 25418314
[TBL] [Abstract][Full Text] [Related]
27. VEGFR2-targeted fusion antibody improved NK cell-mediated immunosurveillance against K562 cells.
Ren X; Xie W; Wang Y; Xu M; Liu F; Tang M; Li C; Wang M; Zhang J
Immunol Res; 2016 Aug; 64(4):1060-70. PubMed ID: 27154226
[TBL] [Abstract][Full Text] [Related]
28. Improving the efficacy of antibody-based cancer therapies.
Carter P
Nat Rev Cancer; 2001 Nov; 1(2):118-29. PubMed ID: 11905803
[TBL] [Abstract][Full Text] [Related]
29. Targeting and therapy of carcinoembryonic antigen-expressing tumors in transgenic mice with an antibody-interleukin 2 fusion protein.
Xu X; Clarke P; Szalai G; Shively JE; Williams LE; Shyr Y; Shi E; Primus FJ
Cancer Res; 2000 Aug; 60(16):4475-84. PubMed ID: 10969795
[TBL] [Abstract][Full Text] [Related]
30. Antibody-IL-2 fusion proteins: a novel strategy for immune protection.
Penichet ML; Harvill ET; Morrison SL
Hum Antibodies; 1997; 8(3):106-18. PubMed ID: 9322080
[TBL] [Abstract][Full Text] [Related]
31. Advances in engineering and delivery strategies for cytokine immunotherapy.
Bohmer M; Xue Y; Jankovic K; Dong Y
Expert Opin Drug Deliv; 2023 May; 20(5):579-595. PubMed ID: 37104673
[TBL] [Abstract][Full Text] [Related]
32. Cancer cell-binding peptide fused Fc domain activates immune effector cells and blocks tumor growth.
Mobergslien A; Peng Q; Vasovic V; Sioud M
Oncotarget; 2016 Nov; 7(46):75940-75953. PubMed ID: 27713158
[TBL] [Abstract][Full Text] [Related]
33. Horse cytokine/IgG fusion proteins--mammalian expression of biologically active cytokines and a system to verify antibody specificity to equine cytokines.
Wagner B; Robeson J; McCracken M; Wattrang E; Antczak DF
Vet Immunol Immunopathol; 2005 May; 105(1-2):1-14. PubMed ID: 15797470
[TBL] [Abstract][Full Text] [Related]
34. Combination of a bispecific antibody and costimulatory antibody-ligand fusion proteins for targeted cancer immunotherapy.
Hornig N; Kermer V; Frey K; Diebolder P; Kontermann RE; Müller D
J Immunother; 2012 Jun; 35(5):418-29. PubMed ID: 22576347
[TBL] [Abstract][Full Text] [Related]
35. Comparative evaluation of bolus and fractionated administration modalities for two antibody-cytokine fusions in immunocompetent tumor-bearing mice.
Puca E; De Luca R; Seehusen F; Rodriguez JMM; Neri D
J Control Release; 2020 Jan; 317():282-290. PubMed ID: 31790729
[TBL] [Abstract][Full Text] [Related]
36. A human cytokine/single-chain antibody fusion protein for simultaneous delivery of GM-CSF and IL-2 to Ep-CAM overexpressing tumor cells.
Schanzer JM; Baeuerle PA; Dreier T; Kufer P
Cancer Immun; 2006 Feb; 6():4. PubMed ID: 16483188
[TBL] [Abstract][Full Text] [Related]
37. Immunocytokines: a novel class of potent armed antibodies.
Pasche N; Neri D
Drug Discov Today; 2012 Jun; 17(11-12):583-90. PubMed ID: 22289353
[TBL] [Abstract][Full Text] [Related]
38. Advances and challenges in developing cytokine fusion proteins as improved therapeutics.
Chang CH; Gupta P; Goldenberg DM
Expert Opin Drug Discov; 2009 Feb; 4(2):181-94. PubMed ID: 23480515
[TBL] [Abstract][Full Text] [Related]
39. The present and future of immunocytokines for cancer treatment.
Gout DY; Groen LS; van Egmond M
Cell Mol Life Sci; 2022 Sep; 79(10):509. PubMed ID: 36066630
[TBL] [Abstract][Full Text] [Related]
40. Concise review: engineering the fusion of cytokines for the modulation of immune cellular responses in cancer and autoimmune disorders.
Ng S; Galipeau J
Stem Cells Transl Med; 2015 Jan; 4(1):66-73. PubMed ID: 25391644
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
